ALZ-801 Phase 3 Program: Lessons & The Path Forward in Developing Targeted Therapies for Alzheimer’s Disease

Time: 4:00 pm
day: Day One


  • Highlighting the benefits of applying genomic stratification of patients for validation of biomarkers from target discovery to therapeutic development
  • Describing discovery of a novel molecular mechanism of action of ALZ- 801, which blocks formation of toxic amyloid oligomers associated with development and progression of Alzheimer’s disease
  • Reviewing development of ALZ-801, a Phase 3, first-in-class, small molecule oral inhibitor of amyloid aggregation and neurotoxicity
  • Emphasizing need for application of Precision Medicine approach in neurodegeneration, based on individual genetic and biological information to advance therapies with the greatest impact for patients